Patients on the firm's SSTR-targeted radiopharmaceutical had improved progression-free survival compared to patients on an mTor inhibitor in a Phase III trial.
After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...
The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.
Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.
“The minimal improvement in survival in recent years is in part related to more people being diagnosed with incidentally detected, well differentiated neuroendocrine tumors, which are less aggressive ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. Exelixis disclosed the ...
Background: In recent years, the incidence of patients with colorectal neuroendocrine neoplasms (CRNENs ... and N0 (83.5%) stages, with well-differentiated tumors (GI 76.1%). The liver was the most ...
Cabometyx is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid ... castration-resistant prostate cancer ...
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroendocrine Tumors. According to GlobalData ... to the next stage in clinical development (PTSR), as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback